Title: Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
Authors: Seguin, Ryan P; Herron, Josi M; Lopez, Vanessa A; Dempsey, Joseph L; Xu, Libin
Published In Chem Res Toxicol, (2019 12 16)
Abstract: Benzalkonium chlorides (BACs) are widely used as disinfectants in cleaning products, medical products, and the food processing industry. Despite a wide range of reported toxicities, limited studies have been conducted on the metabolism of these compounds in animal models and none in human-derived cells or tissues. In this work, we report on the metabolism of BACs in human liver microsomes (HLM) and by recombinant human hepatic cytochrome P450 (CYP) enzymes. BAC metabolism in HLM was NADPH-dependent and displayed apparent half-lives that increased with BAC alkyl chain length (C10 < C12 < C14 < C16), suggesting enhanced metabolic stability of the more lipophilic, longer chain BACs. Metabolites of d7-benzyl labeled BAC substrates retained all deuteriums and there was no evidence of N-dealkylation. Tandem mass spectrometry fragmentation of BAC metabolites confirmed that oxidation occurs on the alkyl chain region. Major metabolites of C10-BAC were identified as ω-hydroxy-, (ω-1)-hydroxy-, (ω, ω-1)-diol-, (ω-1)-ketone-, and ω-carboxylic acid-C10-BAC by liquid chromatography-mass spectrometry comparison with synthetic standards. In a screen of hepatic CYP isoforms, recombinant CYP2D6, CYP4F2, and CYP4F12 consumed substantial quantities of BAC substrates and produced the major microsomal metabolites. The use of potent pan-CYP4 inhibitor HET0016, the specific CYP2D6 inhibitor quinidine, or both confirmed major contributions of CYP4- and CYP2D6-mediated metabolism in the microsomal disappearance of BACs. Kinetic characterization of C10-BAC metabolite formation in HLM demonstrated robust Michaelis-Menten kinetic parameters for ω-hydroxylation (Vmax = 380 pmol/min/mg, Km = 0.69 μM) and (ω-1)-hydroxylation (Vmax = 126 pmol/min/mg, Km = 0.13 μM) reactions. This work illustrates important roles for CYP4-mediated ω-hydroxylation and CYP2D6/CYP4-mediated (ω-1)-hydroxylation during the hepatic elimination of BACs, an environmental contaminant of emerging concern. Furthermore, we demonstrate that CYP-mediated oxidation of C10-BAC mitigates the potent inhibition of cholesterol biosynthesis exhibited by this short-chain BAC.
PubMed ID: 31730751
MeSH Terms: Amidines/pharmacology; Animals; Aryl Hydrocarbon Hydroxylases/chemistry; Aryl Hydrocarbon Hydroxylases/metabolism*; Benzalkonium Compounds/chemistry; Benzalkonium Compounds/metabolism*; Carbon Isotopes/chemistry; Cytochrome P-450 CYP2D6 Inhibitors/pharmacology; Cytochrome P-450 CYP2D6/chemistry; Cytochrome P-450 CYP2D6/metabolism*; Cytochrome P-450 CYP3A Inhibitors/pharmacology; Cytochrome P-450 CYP3A/chemistry; Cytochrome P-450 CYP3A/metabolism*; Disinfectants/metabolism*; Female; Humans; Hydroxylation/drug effects; Kinetics; Male; Mice; Microsomes, Liver/metabolism; Oxidation-Reduction; Quinidine/pharmacology